13958-86-6

Basic information

• Product Name: 3,4-Pyridinediamine,5-methyl-(9CI)
• Synonyms: 3,4-Pyridinediamine,5-methyl-(9CI);5-Methyl-3,4-pyridinediamine;3,4-Diamino-5-methylpyridine;5-Methylpyridine-3,4-diaMine;5-Methylpyridin-3,4-diaMine
• CAS NO: 13958-86-6
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 172.115
• Product Categories: PYRIDINE
• Mol File: 13958-86-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 149 °C
• Boiling Point: 363.1 °C at 760 mmHg
• Flash Point: 200.9 °C
• Appearance: /
• Density: 1.190
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.40±0.24(Predicted)
• CAS DataBase Reference: 3,4-Pyridinediamine,5-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Pyridinediamine,5-methyl-(9CI)(13958-86-6)
• EPA Substance Registry System: 3,4-Pyridinediamine,5-methyl-(9CI)(13958-86-6)

Safety Data

• Hazardous Substances Data: 13958-86-6(Hazardous Substances Data)

Usage

General Description

3,4-Pyridinediamine,5-methyl-(9CI) is a chemical compound with the molecular formula C6H8N2. It is also known as 5-Methyl-3,4-pyridenediamine and has a molecular weight of 108.14 g/mol. This chemical is a pyridine derivative with a methyl group attached to the 5th carbon atom of the pyridine ring. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 3,4-Pyridinediamine,5-methyl-(9CI) is also used as a reagent in organic synthesis and can be found in various laboratory and industrial applications. It is important to handle this chemical with care and to follow proper safety protocols when working with it.

InChI:InChI=1/C6H9N3/c1-4-2-9-3-5(7)6(4)8/h2-3H,7H2,1H3,(H2,8,9)

Upstream product

• 1990-90-5 4-amino-3-methylpyridine 
• 18227-67-3 4-amino-3-methyl-5-nitropyridine 

Downstream Products

• 858939-32-9 2-(2,3-difluorophenyl)-7-methyl-1⁽³⁾H-imidazo[4,5-c]pyridine 

Relevant articles and documents

A model D - amino acid oxidase inhibitor and its preparation and application

The invention provides a novel D- amino acid oxidase inhibitor and a preparation and application thereof. In particular, the invention discloses derivatives of quinoxaline-2,3-diketone, which has a novel structure shown in formula A, as well as a preparation method thereof and an application as an inhibitor of D-amino acid oxidase (DAAO). The compound provided by the invention shows excellent effects of analgesia and blocking morphine analgesia tolerance, and has application value for analgesia, treating opiate drug tolerance, and anti-schizophrenia.

FUSED HETEROCYCLIC COMPOUNDS, HAVING ANGIOTENSIN II ANTAGONISTIC ACTIVITY

Fused heterocyclic compounds of the formula (I): STR1 wherein R. sup.1 is an optionally substituted hydrocarbon residue which may be attached through a hetero atom; R 2 is a group capable of forming an anion or a group convertible thereinto; R 3 is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hetero atom; X is a direct bond or a spacer having an atomic length of two or less between the R 3 group and the ring W group; W is an optionally substituted aromatic hydrocarbon or heterocyclic residue which contains at least one hereto atom; a,c and d are independently selected from the group consisting of one or two optionally substituted carbon atoms and one or two optionally substituted hetero atoms; b and e are independently selected from the group consisting of one optionally substituted carbon atom and one optionally substituted nitrogen atom wherein one of b or e must be nitrogen; the dotted line is a bond to form one double bond; n is an integer of 1 or 2 and when a, which is an optionally substituted carbon atom, is taken together with R 1, the following group: STR2 may form a ring group; provided that when STR3 is a benzimidazole, thieno[3,4-d] imidazole, or thieno[2,3-d] imidazole ring, at least one of the group: STR4 and R 3 is an optionally substituted heterocyclic residue; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.